Back to Stakeholders
Dormant / UnclearResearch, Drug Development & ManufacturingLead program: Pre-clinical

Albert LabsCSE: ABRT

1 Drug Candidate

Very small Canadian biotech developing KRN-101, a natural psilocybin formulation for cancer-related psychological distress. Market capitalisation fell below C$300,000 in 2024, with minimal operating activity and limited financing capacity.

Drug Pipeline

1

KRN-101

Psilocybin
Pre-clinicalPaused
Palliative & End-of-Life Distress

Natural psilocybin formulation for cancer-related psychological distress and palliative care.

Quick Facts

Type
Public Biotech
Ticker
CSE: ABRT
Lead Stage
Pre-clinical
Website
Visit